A variety of mutations may give rise to breast cancer, but scientists generally assume that it starts off with just a few. That's because later-stage breast cancers tend to have more mutations—they are more heterogeneous—than ...
not rated yet |
0
Researchers at Fox Chase Cancer Center have identified a host of small molecules critical to metabolism in cells of triple-negative breast cancer—one of the least understood groups of breast cancer. These molecules, called ...
not rated yet |
0
In results presented at the AACR Annual Meeting 2013, researchers from the University of Colorado Cancer Center show that the Six2 homeoprotein, while not involved in primary tumor growth, allows cells to detach from substrate ...
not rated yet |
0
Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively ...
4 / 5 (1) |
0
Is the era of targeted therapy for breast cancer at hand? It could be, said experts at the Lester and Sue Smith Breast Center at Baylor College of Medicine – at least for a certain population of women.
not rated yet |
0
Johns Hopkins scientists have found out how a gout-linked genetic mutation contributes to the disease: by causing a breakdown in a cellular pump that clears an acidic waste product from the bloodstream. By comparing this ...
not rated yet |
0
|
Once considered part of the "junk" of our genome, much of the DNA between protein-coding genes is now known to be transcribed. New findings by scientists at Fox Chase Cancer Center have identified several dozen transcripts ...
not rated yet |
0
The process of autophagy cleans cells – they wrap up the bad stuff and then dispose of it. And so it stands to reason that inhibiting autophagy would make cancer cells less able to cleanse themselves of chemotherapy and ...
5 / 5 (1) |
0
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative ...
5 / 5 (2) |
0
For women with metastatic, HER2-positive breast cancer, the amount of HER2 on their tumor might determine how much they benefit from a drug called trastuzumab emtansine (T-DM1), according to data from a subanalysis of the ...
not rated yet |
0
Researchers at Moffitt Cancer Center have determined that the overexpression of microRNA-155 (miR-155), a short, single strand of ribonucleic acid encoded by the miR-155 host gene, promotes the growth of blood vessels in ...
5 / 5 (1) |
0
|
A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive ...
5 / 5 (2) |
0
|
More than 100 women per day die from breast cancer in the United States. The odds of developing breast cancer increase for women taking hormone replacement therapy to avoid the effects of menopause. New research by University ...
5 / 5 (1) |
0
A proof-of-concept device is nearly perfect in separating breast cancer cells from blood.
not rated yet |
0
Researchers at the University of California, San Diego School of Medicine have shown that a new imaging dye, designed and developed at UC San Diego Moores Cancer Center, is an effective agent in detecting and mapping cancers ...
5 / 5 (1) |
0
